{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:39:29Z","timestamp":1787168369631,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00405-025-09677-2","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:47:35Z","timestamp":1758224855000},"page":"5675-5682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia"],"prefix":"10.1007","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-3859","authenticated-orcid":false,"given":"Abdullah S.","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Saati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Alkhammash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeb A.","family":"Bulkhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaiya H.","family":"Muathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Abu Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"4","key":"9677_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC (2016) Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 4(4):565\u2013572","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"9677_CR2","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA (2022) Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract 10(6):1434\u201353e9","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9677_CR3","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","volume":"15","author":"C Bachert","year":"2024","unstructured":"Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S et al (2024) The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol 15:1356298","journal-title":"Front Immunol"},{"issue":"6","key":"9677_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jaci.2022.07.023","volume":"150","author":"A Bognanni","year":"2022","unstructured":"Bognanni A, Chu DK, Rank MA, Bernstein J, Ellis AK, Golden D et al (2022) Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis. J Allergy Clin Immunol 150(6):1447\u20131459","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl S29","key":"9677_CR5","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1\u2013464","journal-title":"Rhinology"},{"issue":"9","key":"9677_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clinthera.2022.08.004","volume":"44","author":"GE Davis","year":"2022","unstructured":"Davis GE, Zeiger RS, Emmanuel B, Chung Y, Tran TN, Evans KA et al (2022) Systemic corticosteroid-related adverse outcomes and health care resource utilization and costs among patients with chronic rhinosinusitis with nasal polyposis. Clin Ther 44(9):1187\u20131202","journal-title":"Clin Ther"},{"issue":"2","key":"9677_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/alr.22487","volume":"10","author":"CA Loftus","year":"2020","unstructured":"Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA et al (2020) Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta\u2010analysis of risk factors. Int Forum Allergy Rhinol 10(2):199\u2013207","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"9677_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/jpm14030297","volume":"14","author":"C Cavaliere","year":"2024","unstructured":"Cavaliere C, Masieri S, Begvarfaj E, Loperfido A, Baroncelli S, Cascone F et al (2024) Long-term perspectives on chronic rhinosinusitis with nasal polyps: evaluating recurrence rates after functional endoscopic sinus surgery in the biologics era-a 5-year follow-up study. J Pers Med 14(3):297. https:\/\/doi.org\/10.3390\/jpm14030297","journal-title":"J Pers Med"},{"issue":"Suppl 1","key":"9677_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12070-022-03144-8","volume":"75","author":"AA Mirza","year":"2023","unstructured":"Mirza AA, Abdulazeem HM, Al-Sayed AA, Alandejani TA, Shawli HY, Thompson JY et al (2023) Biologic therapies in chronic rhinosinusitis with nasal polyposis: overview of systematic reviews and updated systematic review. Indian J Otolaryngol Head Neck Surg 75(Suppl 1):650\u2013660","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"5","key":"9677_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","volume":"155","author":"R Kratchmarov","year":"2025","unstructured":"Kratchmarov R, Dharia T, Buchheit K (2025) Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 155(5):1401\u20131410","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9677_CR11","first-page":"e77804","volume":"17","author":"MI Tanase","year":"2025","unstructured":"Tanase MI, Tanase M, Cosgarea M, Radeanu GD, Pop SS, Maniu AA (2025) Biologic treatments for chronic rhinosinusitis with nasal polyps (CRSwNP): a comparative review of efficiency and risks. Cureus 17(1):e77804","journal-title":"Cureus"},{"issue":"5","key":"9677_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S et al (2020) Dual Blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 75(5):1188\u20131204","journal-title":"Allergy"},{"issue":"10209","key":"9677_CR13","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650","journal-title":"Lancet"},{"issue":"1","key":"9677_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11882-025-01192-y","volume":"25","author":"M Rodriguez-Iglesias","year":"2025","unstructured":"Rodriguez-Iglesias M, Calvo-Henriquez C, Martin-Jimenez D, Garcia-Lliberos A, Maza-Solano J, Moreno-Luna R et al (2025) Effect of dupilumab in CRSwNP sinonasal outcomes from real life studies: a systematic review with meta-analysis. Curr Allergy Asthma Rep 25(1):13","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"9677_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2021.1901881","volume":"21","author":"W Fokkens","year":"2021","unstructured":"Fokkens W, Van Der Lans R, Reitsma S (2021) Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther 21(5):575\u2013585","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"9677_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40463-023-00668-z","volume":"52","author":"SA Hardison","year":"2023","unstructured":"Hardison SA, Senior BA (2023) The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP). J Otolaryngol Head Neck Surg 52(1):64","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"2","key":"9677_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/all.15134","volume":"77","author":"RJL van der Lans","year":"2022","unstructured":"van der Lans RJL, Fokkens WJ, Adriaensen G, Hoven DR, Drubbel JJ, Reitsma S (2022) Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 77(2):670\u2013674","journal-title":"Allergy"},{"key":"9677_CR18","unstructured":"De Corso E, Montuori C, De Maio G, D\u2019Auria LM, Rizzuti A, Pacilli MC et al (2025) Dupilumab monthly dose de-escalation maintains efficacy in crswnp: a two-year real-world study. Laryngoscope"},{"issue":"1","key":"9677_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5021\/ad.24.084","volume":"37","author":"H Kim","year":"2025","unstructured":"Kim H, Oh S, Noh H, Joo B, Shim J, Park J et al (2025) Appropriate injection intervals of dupilumab in patients with adult atopic dermatitis: a step toward developing guidelines for daily practice. Ann Dermatol 37(1):39\u201345","journal-title":"Ann Dermatol"},{"issue":"4","key":"9677_CR20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bjd.21628","volume":"187","author":"F Jendoubi","year":"2022","unstructured":"Jendoubi F, Shourik J, Seneschal J, Giordano-Labadie F, Raison-Peyron N, Du-Thanh A et al (2022) Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. Br J Dermatol 187(4):602\u2013603","journal-title":"Br J Dermatol"},{"issue":"12","key":"9677_CR21","doi-asserted-by":"publisher","first-page":"e15933","DOI":"10.1111\/dth.15933","volume":"35","author":"C Patruno","year":"2022","unstructured":"Patruno C, Potestio L, Fabbrocini G, Napolitano M (2022) Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther 35(12):e15933","journal-title":"Dermatol Ther"},{"issue":"1","key":"9677_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","volume":"205","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R et al (2022) Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med 205(1):17\u201335","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"9677_CR23","first-page":"287","volume":"62","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens WJ, De Corso E, Backer V, Bernal-Sprekelsen M, Bjermer L, von Buchwald C et al (2024) EPOS2020\/EUFOREA expert opinion on defining disease States and therapeutic goals in CRSwNP. Rhinology 62(3):287\u2013298","journal-title":"Rhinology"},{"issue":"4","key":"9677_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/pharmaceutics15041031","volume":"15","author":"TY Lin","year":"2023","unstructured":"Lin TY, Wang CY, Wang FY, Kang EY, Hwang YS (2023) Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials. Pharmaceutics 15(4):1031","journal-title":"Pharmaceutics"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09677-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:18:35Z","timestamp":1762892315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09677-2"}},"subtitle":["Extended dupilumab dosing in CRSwNP"],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09677-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at King Abdullah Medical City in Saudi Arabia (identifier: 25-1377).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"All data were anonymized to protect patient confidentiality. Due to the retrospective nature of the research, the requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflicts of interest"}},{"value":"ASA.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"We used AI tools only to improve the English language for clarity. All writing, data, and citations were done solely by the authors, with no AI involvement in the content itself.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial intelligence (AI) use"}}]}}